Gotrade News - Eli Lilly's oral weight loss pill Foundayo recorded 1,390 prescriptions in its debut week ending April 10, according to IQVIA data. The launch marks a pivotal moment in the GLP-1 market as the first oral option that can be taken any time of day without food or water restrictions.
Novo Nordisk's competing oral Wegovy achieved 3,071 U.S. prescriptions in its first four days after launching January 5, setting a higher initial pace. Foundayo's debut week performance trailed Wegovy's early velocity by roughly 55%, though the different measurement periods complicate direct comparison.
Key Takeaways
- Foundayo logged 1,390 prescriptions in week one, a slower start than Wegovy's oral pill but with a key convenience advantage
- Analysts project Foundayo needs 5.4 million prescriptions from April through December to hit its $1.7 billion consensus estimate
- Pricing starts at $149 per month self-pay, with commercial insurance plans covering it for as low as $25 monthly
The FDA approved Foundayo (orforglipron) on April 1, 2026, as the second oral GLP-1 therapy for weight management. Prescriptions became available immediately through LillyDirect with shipping beginning April 6.
Foundayo's primary competitive advantage lies in its dosing flexibility. Unlike oral Wegovy, which must be taken on an empty stomach with specific timing requirements, Foundayo imposes no food or water restrictions.
Self-pay pricing starts at $149 per month for the initial dosage, with commercial insurance plans offering coverage as low as $25 monthly through Lilly's savings card. Medicare coverage is anticipated by July 2026.
Analysts at consensus estimate Foundayo needs approximately 5.4 million prescriptions from April through December to reach $1.7 billion in 2026 revenue. Reaching $2 billion would require roughly 6 million prescriptions across the same period.
Eli Lilly shares traded essentially flat at the time of reporting, declining just 0.11%. The muted stock reaction suggests investors are reserving judgment until several weeks of prescription data establish a clearer trajectory.
The GLP-1 pill market represents the next frontier in obesity treatment, shifting from injectable-only options to oral convenience. Whether Foundayo's flexible dosing translates into sustained prescription momentum will determine the competitive balance against Novo Nordisk through 2026.
Sources
- Investing.com, Lilly's Foundayo hits 1,390 prescriptions in debut week, 2026
- Yahoo Finance, LifeMD Now Offering Eli Lilly's Foundayo, 2026
